Antineoplastic drug contamination in the urine of Canadian healthcare workers
- 700 Downloads
The purpose of this study was to quantify the urine concentration of non-metabolized cyclophosphamide (CP), a commonly administered antineoplastic drug, among potentially exposed Canadian healthcare workers and to identify factors associated with the drug concentration levels.
Participants were asked to provide two sets of 24-h urine samples (at two different sampling events), and the level of CP was quantified using high-performance liquid chromatography–tandem mass spectrometry. In addition to demographic information, participants were surveyed regarding their frequency of handling of antineoplastic drugs, safe drug handling training, and known contact with CP on their work shift. Descriptive and inferential statistical analyses were performed. A backward stepwise linear mixed effect model was conducted to identify the factors associated with urine concentration levels.
We collected 201 urine samples, and 55 % (n = 111) had levels greater than the LOD of 0.05 ng/mL. The mean urinary CP concentration was 0.156 ng/mL, the geometric mean was 0.067 ng/mL, the geometric standard deviation was 3.18, the 75th percentile was 0.129 ng/mL, and the range was <LOD to 2.37 ng/mL. All eight job categories evaluated had some urinary concentrations in excess of the LOD with unit clerks having the highest average level. Workers who worked in the drug administration unit, but were not responsible for administering the drugs to patients, i.e., volunteers, oncologists, ward aides, and dieticians, had the largest proportion of samples exceeding the LOD. We did not find any correlation between the urinary concentration levels and known contact with CP during the work shift. Two factors were found to be significantly associated with urinary CP concentration: (1) Workers who had a duty to handle antineoplastic drugs had higher concentration levels, and (2) workers who had not received safe drug handling training had higher levels of CP in their urine compared with those who had.
The presence of non-metabolized CP in urine confirms that, despite the existence of control measures, a broad range of healthcare workers are at risk of exposure to antineoplastic drugs. A review of the effectiveness of interventions to reduce exposure is warranted and should apply to all healthcare workers involved in some capacity with the hospital medication system. This study identified two factors that are related to the urine CP concentration levels which can serve as an impetus for reducing exposure.
KeywordsAntineoplastic drugs Urinary concentration Healthcare workers Hospital medication system Risk assessment
The authors would like to thank the WorkSafeBC Research Secretariat for funding this Project (RS2008-OG01). We also appreciate the time and cooperation of all participants and their respective facilities. We would like to recognize the assistance of the Dr. Winnie Chu from University of British Columbia who led the team responsible for sample analyses. We would like to acknowledge Jennifer Shum, Pearl Siganporia, and Sarah Chiarello who helped with sample collection efforts.
Conflict of interest
The authors declare that they have no conflict of interest.
- Bos PM, Brouwer DH, Stevenson H, Boogaard PJ, de Kort WL, van Hemmen JJ (1998) Proposal for the assessment of quantitative dermal exposure limits in occupational environments: part 1. Development of a concept to derive a quantitative dermal occupational exposure limit. Occup Environ Med 55(12):795–804CrossRefGoogle Scholar
- Favier B, Gilles L, Desage M, Latour JF (2003) Analysis of cyclophosphamide in the urine of antineoplastic drugs handlers. Bull Cancer 90(10):905–909Google Scholar
- Hon C-Y, Astrakianakis G, Danyluk Q, Chu WC (2011a) Pilot evaluation of dermal contamination by antineoplastic drugs among hospital pharmacy personnel. Can J Hosp Pharm 64(5):327–332Google Scholar
- Hon C-Y, Barzan C, Astrakianakis G (2014a) Identification of knowledge gaps regarding healthcare workers’ exposure to antineoplastic drugs: review of literature, North America versus Europe. Saf Health Work. doi: 10.1016/j.shaw.2014.06.001
- Hornung R, Reed L (1990) Estimation of average concentration in the presence of nondetectable values. Am Ind Hyg J 5(1):46–51Google Scholar
- NIOSH (2004) Preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings (2004–2165). Accessed 30 Nov 2011. http://www.cdc.gov/niosh/docs/2004-165/
- Pethran A, Schierl R, Hauff K et al (2003) Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int Arch Occup Environ Health 76(1):5–10Google Scholar
- Ritchie MA, McAdams C, Fritz N (2000) Exposure risk in the handling and administration of chemotherapy agents: a review and synthesis of the literature. Online J Knowl Synth Nurs 7(1):51–60Google Scholar
- Sessink PJ, Van de Kerkhof MC, Anzion RB, Noordhoek J, Bos RP (1994) Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? Arch Environ Health 49(3):165–169CrossRefGoogle Scholar
- US EPA (2011) Series 875: chemical safety and pollution prevention. Accessed 26 Oct 2011. http://www.epa.gov/ocspp/pubs/frs/publications/Test_Guidelines/series875.htm